A prospective, open-label, multicenter study to evaluate the pharmacokinetic, efficacy, and safety of Nonacog-alfa in previously treated patients with moderately severe to severe haemophilia B
Latest Information Update: 16 Mar 2016
At a glance
- Drugs Nonacog alfa (Primary)
- Indications Haemophilia B
- Focus Pharmacokinetics
- Sponsors Pfizer
Most Recent Events
- 16 Mar 2016 New trial record
- 08 Mar 2016 Results published in the Clinical Therapeutics.